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Abstract We study the association between three protein
kinase C, eta gene polymorphisms (+8134C/T, rs912620,
rs959728), and susceptibility to rheumatoid arthritis. One
hundred French Caucasian rheumatoid arthritis trio families
were genotyped. Relative quantification of protein kinase
C, eta mRNA expression was performed from whole blood
in 24 unrelated rheumatoid arthritis patients and in 16
healthy controls. Our results showed no significant associ-
ation or linkage between the protein kinase C, eta poly-
morphisms, and rheumatoid arthritis. The protein kinase C,
eta mRNA was expressed at lower level in rheumatoid
arthritis unrelated patients than in healthy controls. This
study shows that protein kinase C, eta gene is not a
Rheumatoid Arthritis major susceptibility genetic factor in
the French Caucasian population. Furthermore, the lower
expression of this gene in rheumatoid arthritis patients
comparing to healthy controls suggests that protein kinase
C, eta could be associated with the patho-physiologic
mechanism of rheumatoid arthritis.
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Introduction
Rheumatoid Arthritis (RA) is a chronic inflammatory
disease characterized by persistent joint synovial tissue
inflammation associated with the destruction of affected
joints [1]. During the RA development, autoreactive T cells
are activated and recruited to joints mediating the synovial
inflammation and finally causing tissue damage and
cartilage and bone invasion [2]. Previous studies have
shown that many autoreactive T cells, expressing high
levels of CD45RO, are present in synovial fluid of RA
patients [3] demonstrating that these autoreactive T cells are
activated and have adopted an effector/memory phenotype
[4]. Immunosuppressive drugs or anti-cell antibodies were
used to eliminate or inhibit T cells causing an amelioration
of the disease [5]. Hence, it is apparent that autoreactive T
cells play important roles in synovial tissue inflammation in
RA patients. The biologic mechanism of these autoreactive
T cells in RA remains poorly studied.
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Protein kinase C, eta (PRKCH) gene, which encodes the
η isozyme of protein kinase C (PKCη), is a good functional
candidate for susceptibility to RA because protein kinase C
(PKC) plays an important role in signal transduction
controlling T-cell activation. The PKC gene family consists
of more than 11 members, including PRKCH/PKCη, and
their individual products have been revealed to be involved
in different cellular biological functions in various cell
types [6]. Recent papers suggest that some isozymes of
PKC are involved in critical functions of T cells [7, 8].
A previous study reported a significant association (P<
0.05) for a landmark SNP (rs767755), located in intron 2 of
the PRKCH gene, with RA in a case-control Japanese
population. Subsequent analysis of additional single nucle-
otide polymorphisms (SNPs) within this gene revealed
multiple SNPs located in three distinct linkage disequilibri-
um blocks to be significantly associated with RA. In each
linkage disequilibrium block the most significant associated
SNP was reported (+8134C/T, rs912620, and rs959728).
Furthermore, they have shown that PRKCH gene was
expressed at high levels in resting T cells and this expression
was downregulated by immune responses suggesting that
PKCη is involved in signaling pathways to T cells [9].
In this study, we tested PRKCH +8134C/T, rs912620, and
rs959728 SNPs for RA association and linkage in 100 French
Caucasian trios. Moreover, the level of expression of PRKCH
mRNA in 24 French Caucasian unrelated RA patients and in
16 French Caucasian healthy controls and the association
between haplotypes of the SNPs tested and the level of
expression in 24 unrelated RA patients were studied.
Methods
Patients and Healthy Controls
The study was approved by the Ethics Committees of
Hôpital Bicêtre and Hôpital Saint Louis (Paris, France) and
all subjects provided informed consent. One hundred RA
trio families (one patient and both healthy parents) with the
four grandparents of French Caucasian origin were
recruited through a national media campaign. Character-
istics of the RA trio families sample are reported in Table I.
Among the 24 French Caucasian unrelated RA patients, 18
were women (mean±SD age at enrolment 53.6±12.1).
Depending on the swollen/tender joint count at the time of
the study, there were 17 severe RA patients (minimum five
inflamed joints) and seven mild RA patients (less than five
active joints). All RA patients have received disease-
modifying anti-rheumatoid drugs (DMARDs) and cortico-
steroid therapy before the inclusion in the study. All RA
patients satisfied the revised criteria of the American
College of Rheumatology [10] according to the rheumatol-
ogist in charge of the patient. A rheumatologist university
fellow reviewed all clinical data. Between the 16 French
Caucasian healthy controls, 11 were women (mean±SD age
at enrolment 47.8±7.5).
Molecular Genotyping Method
Genomic DNA of the 100 French Caucasian RA trio
families and the 24 French Caucasian unrelated RA patients
was isolated and purified from fresh peripheral blood
leukocytes according to standard protocols. Genotyping of
the PRKCH +8134C/T polymorphism was performed by
the polymerase chain reaction (PCR) followed by restric-
tion fragment length polymorphism (PCR-RFLP) method
[11]. The designed primers were: sense 5′ATGTGGTTTAT
TATAGTATTCTACTTT3′ and anti-sense 5′ TACTCACC
TGTTCCTACCTGCA 3′. Primers were tested using the
BLAST algorithm to ensure that only the PRKCH gene was
amplified. PCR amplification was performed on each
sample in a 25-μl reaction volume consisting of 10× PCR
buffer (Perkin-Elmer, Boston, MA, USA), 1.25 mM of each
dNTP, 1.25 U of Taq Gold DNA polymerase (Perkin-
Elmer), 3 mM MgCl2, 0.0125 nM of the two primers
(Invitrogen, Cergy Pontoise, France) and 50 ng of genomic
DNA, diluted to the final volume with H2O on Eppendorf
thermocycler. The PCR program was carried out using the
following amplification protocol: 37 cycles of denaturation
at 96°C for 30 s, with annealing temperature at 59°C for
30 s followed by an elongation step at 72°C for 1 min. One
final cycle of the extension was performed at 72°C for
10 min. A 360-bp amplified fragment was digested with
NlaIII (Ozyme, Montigny Le Bretonneux, France) generat-
Table I Characteristics of
Rheumatoid Arthritis (RA) in-
dex cases from the investigated
sample
*DRB1*0101, DRB1*0102,
DRB1*0401, DRB1*0404,
DRB1*0405, DRB1*0408,
DRB1*1001.
RA patients (n=100)
Females (%) 87
Mean age (± standard deviation, SD) at disease onset (years) 32 (±10)
Mean (± SD) disease duration (years) 18 (±7)
RA patients with bone erosions (%) 90
RA patients seropositive for rheumatoid factor (%) 81
RA patients seropositive for anti-cycle citrullinated peptides antibodies (%) 78
RA patients carrying at least one HLA-DRB1shared epitope allele (%)* 78
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ing two fragments (187 and 139 bp) when the restriction
site located at the SNP locus was present (C allele). Two
independent investigators assessed genotypes blindly. Geno-
typing of the PRKCH rs912620 and rs959728 SNPs was
carried out with a Taqman 5′ allelic discrimination assay on an
ABI 7500 real-time PCR machine (assays: C__7600119_10,
C__7600090_10, respectively; Applied Biosystems, Foster
City, CA, USA). Allele-specific probes were labeled with
the fluorescent dyes VIC and FAM. PCR reaction was
carried out in a total volume of 15 μl with the following
amplification protocol: denaturation at 95°C for 10 min,
followed by 40 cycles of denaturation at 92°C for 15 s,
annealing and extension at 60°C for 1 min. Genotyping of
each sample was automatically attributed using the sodium
dodecyl sulfate (SDS) software for allelic discrimination.
Ten percent of the samples chosen at random were
genotyped again for quality control.
PRKCH mRNA Expression by Real-Time Quantitative
Reverse Transcription-PCR
Total RNA of the 24 French Caucasian unrelated RA
patients and 16 French Caucasian healthy controls from
whole blood was extracted using a PAXgene Blood RNA
kit (Qiagen, Hilden, Germany). The measure of the RNAs
concentration was performed using the RNA RiboGreen
dye (Invitrogen). The integrity of the RNAs was analyzed
using the Agilent 2100 Bionalyzer (Agilent, Santa Clara,
CA, USA). Reverse-transcription was performed in a total
volume of 20 μl with SuperScript™ III First-Strand
Synthesis SuperMix for qRT-PCR (Invitrogen) using 1 μg
of each total RNA and random hexamers according to the
manufacturer’s protocol. The kit includes RNaseOUT™
recombinant ribonuclease inhibitor as an RNase protector.
Real-time quantitative reverse transcriptase PCR (RT-PCR)
analysis was executed on an ABI Prism 7500 machine,
using TaqMan Gene Expression Assays probes (Applied
Biosystems) for PRKCH (Hs00178933_m1) and TaqMan
Endogenous Controls probes (Applied Biosystems) for
ACTB (β-actin), GAPDH (Glyceraldehyde-3-phosphate
dehydrogenase) and B2M (β-2-microglobulin). Each sam-
ple was tested in duplicate and a sample without template
was included in each run as a negative control. The
expression level of the PRKCH transcript was quantified
using the threshold cycle (Ct) method and normalized to the
amount of ACTB, GAPDH, and B2M. Samples showing Ct
values>35 and duplicates with a Ct>0.3 were retested.
Haplotype Assignment
The PRKCH gene haplotypes obtained taking into account
the unphased SNP genotype data of the 24 unrelated RA
patients was performed using fastPHASE 1.2 software [12].
Statistical Analysis
After the hypothesis of an RA association profile of
PRKCH in a French Caucasian population similar to that
observed in Japanese RA patients, we used the reported
allelic frequencies of the PRKCH +8134C/T SNP in
Japanese RA patients (17%) and in controls (22.2%) [9].
Using the binomial distribution, we had 88.5% power to
detect a trend in favor of an association: probability of
having the frequency in patients superior to that in controls
following the binomial distribution for n observations (0–100
in our trio index) [13].
The Hardy–Weinberg equilibrium was checked in the
control group (constituted by the nontransmitted parental
chromosomes from trio) before analysis.
The linkage and association analysis relied on the
Transmission disequilibrium test (TDT) [14], which com-
pares, for a given allele, its transmission from heterozygous
parents to RA patients, with the transmission expected from
Mendel’s law (i.e., 50%). Secondly, we used the genotypes
relative risk (GRR), which compares the affected
offspring’s genotype with the control genotype derived
from nontransmitted parental chromosomes, using the
method proposed by Lathrop [15]. Statistical significance
was considered for P<0.05.
Results of relative mRNA expression are presented as
the mean±standard deviation percentage. Statistical analy-
sis of the relative expression of the PRKCH in RA patients
and healthy controls was performed using the Mann–
Whitney test and P<0.05 was considered significant.
Table II Transmission Disequilibrium Test (TDT) for PRKCH +8134C/T, rs912620, rs959728 SNPs, and RA (100 Trio families)
PRKCH SNPs Allele Transmitted Nontransmitted T (%) P value
+8134C/T C 40 40 50 1
rs912620 (G>T) G 42 46 47.7 0.67
rs959728 (C>T) C 17 22 43.6 0.42
T=Percentage of transmission from heterozygous parents
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The association between haplotypes of the SNPs tested
and the level of expression in 24 unrelated RA patients was
assessed by the Mann–Whitney test. Data are expressed as
the mean±standard deviation and P<0.05 was considered
significant.
Results
Hardy–Weinberg Equilibrium Check
The PRKCH +8134C/T, rs912620 and rs959728 SNPs were
in Hardy–Weinberg equilibrium in the control sample
investigated.
Test for Linkage and Association in the Trio RA Families
We test the PRKCH putative susceptibility alleles +8134C,
rs912620-T and rs959728-T for which association with RA
was the most significant in the case-control Japanese
population [9].
We did not observe a linkage and association between
the +8134C allele and RA: there was an equal transmis-
sion of +8134C allele and +8134T allele from heterozy-
gous parents (40 transmitted vs. 40 nontransmitted, P=1)
(Table II). There was no significant overtransmission of the
rs912620-T allele from heterozygous parents (46 transmit-
ted vs. 42 nontransmitted, P=0.67) (Table II). The same
result is observed for the rs959728-C allele (22 transmitted
vs. 17 nontransmitted, P=0.42) (Table II). The GRR
analysis of the PRKCH +8134C/T, rs912620, and
rs959728 SNPs showed no significant (P>0.05) association
of the homozygous or heterozygous genotypes for suscep-
tibility alleles with RA (Table III). The TDT analysis of
PRKCH +8134C/T-rs912620-rs959728 haplotypes did not
reveal any significant association for the seven haplotypes
estimated (data not shown).
Expression Analysis
A relative quantification of PRKCH mRNA expression was
performed in total RNA from whole blood in 24 unrelated
RA patients and in 16 healthy controls. PRKCH was
expressed in RA patients at lower level (−92%; P<
0.0001) than in healthy controls (Fig. 1). Figure 2 reported
the relative quantification of PRKCH mRNA in severe and
Table III Genotype Relative
Risk (GRR) for PRKCH
+8134C/T, rs912620, rs959728
SNPs, and RA (100 Trio
families)
PRKCH SNPs Genotypes Lathrop P value
(one genotype vs the others)
Global P value
+8134C/T CC 0.63 1
CT
TT 0.44
rs912620 (G>T) GG 0.46 0.90
GT
TT 0.89
rs959728 (C>T) CC 0.28 0.61
CT
TT 0.58
Fig. 1 Levels of PRKCH mRNA expression in peripheral blood from
RA unrelated patients and healthy controls. PRKCH mRNA levels
were determined by real-time quantitative RT-PCR and normalized to
ACTB, GAPHD, and B2M levels. The expression level of the PRKCH
transcript was quantified using the threshold cycle (Ct) method. Data
are presented as the mean±SD percentage of the PRKCH mRNA
expression. *P<0.0001 versus Controls, by Mann–Whitney test.
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mild RA patients. The expression of PRKCH in severe RA
patients was higher than in mild RA patients (P=0.008).
We selected three haplotype combinations: CTT/CTT
(haplotype homozygous for the susceptible alleles), CTT/X
(haplotype heterozygous for the susceptible alleles), and
X/X (haplotype with no susceptible alleles). In the set of 24
unrelated RA patients, there were four RA patients with
CTT/X haplotype, 20 with X/X and no one with CTT/CTT.
Although the expression of PRKCH mRNA was lower in
RA patients with CTT/X haplotype compared to X/X
haplotype (Fig. 3), we did not observe a significant
association (P=0.94).
Discussion
This study was designed to test the PRKCH +8134C/T,
rs912620 and rs959728 SNPs for linkage to, and associa-
tion with, RA in a French Caucasian familial population. In
addition, we studied the level of expression of PRKCH
mRNA in RA patients and in healthy controls and the
association between haplotypes of the SNPs tested and the
level of expression in RA patients.
Takata et al. [9] described the +8134C, rs912620-T, and
rs959728-T alleles from SNPs located in three different
linkage disequilibrium blocks susceptible for RA. We have
confirmed that these susceptibility alleles were not in
linkage disequilibrium in the French Caucasian population
(data not shown). In the linkage disequilibrium block D
described by Takata et al. [9], we have chosen to test the
rs959728 SNP, which is more associated to RA than
rs2230500 SNP (P=0.00011 vs P=0.0016). This functional
SNP rs2230500 located in exon 9 (V3741I) was reported to
increase the risk of cerebral infarction [16]. Our results
showed a clear absence of RA linkage and association in
the population investigated for the three SNPs tested. In
good agreement with the TDT analysis, the GRR revealed a
lack of association between the different genotypes and RA.
Fig. 2 Levels of PRKCH mRNA expression in peripheral blood from
severe and mild RA patients. PRKCH mRNA levels were determined
by real-time quantitative RT-PCR and normalized to ACTB, GAPHD,
and B2M levels. The expression level of the PRKCH transcript was
quantified using the threshold cycle (Ct) method. Data are presented
as themean±SD percentage of thePRKCH mRNA expression. *P=0.008
versus severe RA patients, by Mann–Whitney test.
Fig. 3 Association between the level of PRKCH mRNA expression
and PRKCH haplotype (+8134C/T-rs912620-rs95972824) in RA
patients. PRKCH mRNA levels were determined by real-time
quantitative RT-PCR and normalized to ACTB, GAPHD, and B2M
levels. The expression level of the PRKCH transcript was quantified
using the threshold cycle (Ct) method. Four samples in the CTT/X
haplotypes and 20 in the X/X haplotypes were analyzed. Data are
presented as the mean±SD percentage of the PRKCH mRNA
expression. *P=0.94 versus X/X haplotypes, by Mann–Whitney test.
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The linkage analysis of PRKCH +8134C/T–rs912620–
rs959728 haplotypes was not significant as none of the
seven haplotypes described were overtransmitted (data not
shown). The results were obtained with a particularly robust
method, the Transmission Disequilibrium Test [14], which
compares, for a given allele, its transmission from hetero-
zygous parents to RA patients, with the transmission
expected from Mendel’s law (i.e., 50%). This family-based
analysis avoids imperfect population match between
patients and controls and permits the direct test of the
Mendel’s law. These results allowed us to exclude PRKCH
as a major significant genetic factor in RA in a French
Caucasian population. There were several genetic studies
that reported differences in ethnic variations of polymor-
phisms associated with RA as PADI4 and SLC22A4 genes
[17–19]. Moreover, PRKCH locus was not included among
the suggested 19 non-HLA regions in the French Caucasian
population [20]. The last genome-wide association study in
a UK Caucasian population had found 9 SNPs that map to
loci not associated previously to RA [21]. However,
PRKCH locus was not present in these regions. Thus, other
populations need to be studied to define extensively the
involvement of this gene in the genetics of RA.
Even some PKC isozymes have been suggested to be
involved in important functions of T cells [7, 8] the
physiological function of PKCη in T cells has not yet been
well documented and the pathway by which PRKCH SNPs
may influence RA risk remains unknown.
This study is the first to show that PRKCH was expressed
in RA patients at a lower level than in non-RA controls in
peripheral blood cells. This result suggests that expression of
the PRKCH gene is regulated through immune responses.
This observation confirms the study of Takata et al. [9] who
have shown that PRKCH gene is expressed in resting CD4+
cells (T helper/inducer cells) or CD8+ cells (T suppressor/
cytotoxic cells) at higher levels than in resting CD19+ cells
(B cells) or CD14+ cells (monocytes) and the expression in
these cells were significantly downregulated by activation.
Our data also show the PRKCH mRNA highly expressed
in severe RA patients comparing to mild RA patients,
supporting the increase of expression of PRKCH during the
progression of the disease from mild to severe RA. PKCη
functions have been associated to the cytokine signaling
cascade in monocytes and macrophages. Indeed, plasma
levels of nitric oxide, a mediator of inflammation, were
shown to be elevated in patients with severe RA, and a
positive association between PRKCH and inducible nitric
oxide synthase (iNOS) expression was observed in periph-
eral blood monocyte-derived macrophages from severe RA
patients. Furthermore, this coexpression was not present in
healthy controls [22].
Heale et al. [23] have confirmed these results reporting a
PKCη-expression phenotype in monocytes for mild and
severe RA patients and not for healthy controls. Moreover,
there was a progressive and concordant expression of
PKCη and iNOS phenotypes in monocytes from RA
patients associated with the severity of the disease.
These studies provided evidence supporting the possible
involvement of PKCη in immunologic activities of T cells,
monocytes and macrophages, whereas our study highlight-
ed an overall expression of PRKCH gene in whole blood
from RA patients. The association of PRKCH differential
expression and the patho-physiologic mechanism in RA
should be then further investigated.
The relation between haplotypes and expression level of
PRKCH gene was not identified, as the expression of
PRKCH mRNA was lower in RA patients with CTT/X
haplotype comparing to X/X haplotype but without signif-
icance. Nevertheless, the determination of haplotype effects
should require an extensive examination of expression in
different cell subsets and RA states.
Conclusions
We provided evidence against the involvement of the
PRKCH gene in the genetics of RA in a French Caucasian
familial population. However, replication studies in other
independent Caucasian populations are required to confirm
these results. Our study is the first to show that PRKCH
was expressed in RA patients at lower level than in non-RA
controls in peripheral blood cells. Further investigations in
the regulation of PRKCH expression in RA are necessary to
prove the involvement of PKCη molecular mechanisms in
disease susceptibility, more specifically in signaling path-
ways of RA-specific immune response.
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